Ocedurenone Explained

Legal Status:	Investigational
Cas Number:	1359969-24-6
Pubchem:	75593324
Unii:	L46509378R
Synonyms:	KBP-5074
Iupac Name:	4-[(3''S'',3a''R'')-3-Cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-''f'']quinolin-2-yl]-2-chlorobenzonitrile
C:	28
H:	30
Cl:	1
N:	5
O:	2

Ocedurenone, formerly known as KBP-5074,^[1] is a nonsteroidal, selective mineralocorticoid receptor antagonist that is being developed to treat hypertension in patients with chronic kidney disease with less risk of hyperkalemia than existing treatments.^{[2] [3]} In 2023, KPB Biosciences entered into talks to sell the drug to Novo Nordisk for USD$1.3 billion. It is a small molecule drug administered orally and is in a Phase III trial that is scheduled to complete in 2024.^{[4] [5]}

Notes and References

1. Web site: Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease . Nephrology . 4 November 2023 . 16 March 2023.
2. Pitt . Bertram . Jaisser . Frederic . Bakris . George . An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension . Expert Opinion on Investigational Drugs . October 2021 . 30 . 10 . 1017–1023 . 10.1080/13543784.2021.1985462 . 1744-7658. free .
3. Bakris . George . Pergola . Pablo E. . Delgado . Belkis . Genov . Diyan . Doliashvili . Tamar . Vo . Nam . Yang . Y. Fred . McCabe . James . Benn . Vincent . Pitt . Bertram . Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study . Hypertension . July 2021 . 78 . 1 . 74–81 . 10.1161/HYPERTENSIONAHA.121.17073. free . 8189259 .
4. Web site: Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from Singapore Biotech . BioSpace . 4 November 2023.
5. News: Novo Nordisk in $1.3 bln deal to buy hypertension drug . 4 November 2023 . Reuters . 16 October 2023 . en.